Mr. Richard MacKay reports

VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS

Al Moghaddam has joined Valeo Pharma Inc.'s board of directors.

"We are very pleased to welcome Mr. Moghaddam to the Valeo board of directors. He is a seasoned and recognized senior pharmaceutical executive with a long track record of superior performance in value creation and industry-leading growth delivery," said Richard MacKay, chairman. "We look forward to the board benefiting from his valuable insight and perspective."

More about Mr. Moghaddam

Mr. Moghaddam is a customer-centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med tech and consumer markets. He is a strong visionary, process-driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva and Pharmascience for outstanding performance in creating value.

Mr. Moghaddam has cross-functional experience in product life cycle management, sales, business development and licensing, market access, marketing, finance, and mergers and acquisitions.

About Valeo Pharma Inc.

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Headquartered in Kirkland, Que., Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

We seek Safe Harbor.